

- M., Shaw D., Bruggmann P., Gane E., Fraser C., Marks P., Applegate T.L., Quiene S., Siriragavan S., Matthews G.V., Dore G.J., Grebely J., SIMPLIFY study group (2018). Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. *Int J Drug Policy*, Dec, 62: 14-23. doi: 10.1016/j.drugpo.2018.08.013.
- Dillon J.F., Lazarus J.V., Razavi H.A. (2016). Urgent action to fight hepatitis C in people who inject drugs in Europe. *Hepatol Med Policy*, Jun 30, 1: 2. doi: 10.1186/s41124-016-0011-y.
- Dore G.J., Altice F., Litwin A.H., Dalgard O., Gane E.J., Shibolet O., Luetkemeyer A., Nahass R., Peng C.Y., Conway B., Grebely J., Howe A.Y., Gendrano I.N., Chen E., Huang H.C., Dutko F.J., Nickle D.C., Nguyen B.Y., Wahl J., Barr E., Robertson M.N., Platt H.L., C-EDGE CO-STAR Study Group (2016). Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. *Ann Intern Med.*, Nov 1, 165(9): 625-634. doi: 10.7326/M16-0816.
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2019). Hepatitis C: models of care for drug services in Europe. www.emcdda.europa.eu/system/files/attachments/11482/Hepatitis-C-new-models-of-care-for-drugs-services_WEB.pdf.
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2019). Monitoring the elimination of viral hepatitis as a public health threat among people who inject drugs in Europe. www.emcdda.europa.eu/system/files/publications/11796/Technical%20report_The%20elimination%20barometer%20for%20viral%20hepatitis%20among%20PWID%20in%20Europe_0.pdf.
- European Monitoring Centre for Drugs and Drug Addiction. European drug report 2019, trends and developments. www.emcdda.europa.eu/system/files/publications/11364/20191724_TDAT19001E_NN_PDF.pdf.
- Flamm S., Mutimer D., Asatryan A., Wang S., Rockstroh J., Horsmans Y., Kwo P.Y., Weiland O., Villa E., Heo J., Gane E., Ryder S.D., Welzel T.M., Ruane P.J., Agarwal K., Ng T.I., Xue Z., Lovell S.S., Krishnan P., Kopecky-Bromberg S., Trinh R., Mensa F.J., Wyles D.L. (2019). Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis. *J Viral Hepat.*, Mar, 26(3): 337-349. doi: 10.1111/jvh.13038.
- Fourati S., Feld J.J., Chevaliez S., Luhmann N. (2018). Approaches for simplified HCV diagnostic algorithms. *J Int AIDS Soc.*, Apr, 21(Suppl. Suppl. 2): e25058. doi: 10.1002/jia2.25058.
- Franco R.A., Galbraith J.W., Overton E.T. (2018). Saag MS. Direct-acting antivirals and chronic hepatitis C: towards elimination. *Hepatome Res*, 4: 74. doi: 10.20517/2394-5079.2018.94.
- Grebely J., Sherman K.E., Baumgarten A., Conway B., Jackson D., Asselah T., Gschwantler M., Tomasiewicz K., Aguilar H., Asatryan A., Hu Y., Mensa F.J. (2019). Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. *Drug Alcohol Depend.*, Jan 1, 194: 487-494. doi: 10.1016/j.drugalcdep.2018.11.007.
- Grebely J., Dore G.J., Morin S., Rockstroh J.K., Klein M.B. (2017). Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there? *J Int AIDS Soc.*, 20(1): 22146. doi: 10.7448/IAS.20.1.22146.
- Grebely J., Oser M., Taylor L.E., Dore G.J. (2013). Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. *J Infect Dis.*, Mar, 207(Suppl. 1): S19-25. doi: 10.1093/infdis/jis928.
- Grebely J., Haire B., Taylor L.E., Macneill P., Litwin A.H., Swan T. *et al.* (2015). Excluding people who use drugs or alcohol from access to hepatitis C treatments – is this fair, given the available data? *J Hepatol.*, 63: 779-82.
- Grebely J., Dore G.J., Zeuzem S. *et al.* (2016). Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. *Clin Infect Dis.*, 63(11): 1479-1481.
- Grebely J., Hajarizadeh B., Dore G.J. (2017). Direct-acting antiviral agents for HCV infection affecting people who inject drugs. *Nat Rev Gastroenterol Hepatol.*, 14(11): 641-651.
- Harris M., Jolly E., Martin A., Wells H., Rhodes T. (2012). Barriers and facilitators to Hepatitis C treatment for People who inject drugs A qualitative study. www.euro.who.int/__data/assets/pdf_file/0011/179750/Barriers-and-facilitators-to-hepatitis-C-treatment-for-PWID-A-qualitative-study-June-2012-rev-5.pdf.
- Kattakuzhy S., Mathur P., Gross C. *et al.* (2018). High SVR in PWID with HCV despite imperfect medication adherence: data from the anchor study. *Hepatology*, 68(S1). doi: 10.1002/hep.30256.
- Kattakuzhy S., Gross C., Emmanuel B., Teferi G., Jenkins V., Silk R., Akoth E., Thomas A., Ahmed C., Espinosa M., Price A., Rosenthal E., Tang L., Wilson E., Bentzen S., Masur H., Kottitil S. (2017). Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. *Ann Intern Med.*, Sep 5, 167(5): 311-318. doi: 10.7326/M17-0118.
- Lazarus J.V., Sperle I., Maticic M., Wiessing L. (2014). A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. *BMC Infect Dis.*, 14(Suppl. 6): S16. doi: 10.1186/1471-2334-14-S6-S16.
- Lazarus J.V., Safreed-Harmon K., Thursz M.R., Dillon J.F., El-Sayed M.H., Elsharkawy A.M., Hatzakis A., Jadoul M., Prestileo T., Razavi H., Rockstroh J.K., Wiktor S.Z., Colombo M. (2018). The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. *Semin Liver Dis.*, Aug, 38(3): 181-192. doi: 10.1055/s-0038-1666841.
- Litwin A.H., Drolet M., Nwankwo C., Torrens M., Kastelic A., Walcher S., Somaini L., Mulvihill E., Ertl J., Grebely J. (2019). Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE study. *J Viral Hepat.*, Sep, 26(9): 1094-1104. doi: 10.1111/jvh.13119. Epub 2019 Jun 11.
- Marinho R.T., Barreira D.P. (2013). Hepatitis C, stigma and cure. *World J Gastroenterol*, 19: 6703-9.
- Stein J.A., Nyamathi A. (2004). Correlates of hepatitis C virus infection in homeless men: a latent variable approach. *Drug Alcohol Depend*, 75: 89-95.
- Maticic M., Videcnik Zorman J., Gregorcic S., Schatz E., Lazarus J.V. (2019). Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. *Harm Reduct Journal*, May, 9, 16(1): 32. doi: 10.1186/s12954-019-0303-9.
- Molinario S., Resce G., Alberti A., Andreoni M., D'Egidio P.P.F., Leonardi C., Nava F.A., Pasqualetti P., Villa S. (2019). Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics. *Drug Alcohol Rev.*, Sep, 38(6): 644-655. doi: 10.1111/dar.12978.
- Murdock M., Brizzi M.B., Perez O., Badowski M.E. (2019). Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review. *Infect Dis Ther*, 8: 23-32. doi: 10.1007/s40121-018-0228-8.
- Norton B.L., Fleming J., Bachhuber M.A., Steinman M., DeLuca J., Cunningham C.O., Johnson N., Laraque F., Litwin A.H. (2017). *Int J Drug Policy*, 47: 196-201.
- Palmateer N., Hutchinson S., McAllister G., Munro A., Cameron S., Goldberg D., Taylor A. (2014). Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. *J Viral Hepat*, Jan, 21(1): 25-32. doi: 10.1111/jvh.12117.
- Stein J.A., Andersen R.M., Robertson M., Gelberg L. (2012). Impact of hepatitis B and C infection on health services utilization in homeless adults: a test of the Gelberg-Andersen behavioral model for vulnerable populations. *Health Psychol*, 31: 20-30.
- Terrault N.A. (2019). Hepatitis C elimination: challenges with under-diagnosis and under-treatment. *F1000Res.*, Jan 14, 8, pii: F1000 Faculty Rev-54. doi: 10.12688/f1000research.15892.1.
- World Health Organization Europe (2017). Action plan for the health sector response to viral hepatitis in the WHO European region. www.euro.who.int/data/assets/pdf_file/0008/357236/Hepatitis-9789289052870-eng.pdf.
- Wiessing L., Ferri M., Grady B., Kantzanou M., Sperle I., Cullen K.J., EMCDDA DRID group, Hatzakis A., Prins M., Vickerman P., Lazarus J.V., Hope V.D., Matheï C. (2014). Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. *PLoS One*, 9(7): e103345. doi: 10.1371/journal.pone.0103345.